Attached files

file filename
EX-99 - PRESS RELEASE - Oncotelic Therapeutics, Inc.newsrelease.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2013


OXiGENE, Inc.
(Exact name of registrant as specified in its charter)


Delaware
 
0-21990
 
13-3679168
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


701 Gateway Boulevard, Suite 210, South San Francisco, CA

94080
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (650) 635-7000


________________________________________________________________________________
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  [   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  [   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  [   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  [   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On February 6, 2013 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

    Exhibit 99.1.       Press release dated February 6, 2013


SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OXiGENE, Inc.

Date: February 6, 2013 By:   /s/   PETER J. LANGECKER
Peter J. Langecker
Chief Executive Officer




  Exhibit Index
  99.1 Press release dated February 6, 2013